Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Combinatorial Chemistry & High Throughput Screening
  4. Fast Track Articles
  5. Fast Track Article
image of Unveiling the Interplay between Dopamine-like Molecules and Β-Amyloid Peptide: A Combined Molecular Dynamic and DFT Approach

Abstract

Aims

This study aims explore the impact of catechol, dopamine, and L-DOPA on the stability and toxicity of β-amyloid peptides, which play a key role in the neurodegenerative process of Alzheimer's disease, to assess their potential as therapeutic agents.

Background

Alzheimer's disease is marked by the aggregation of β-amyloid peptides, which contribute to neurodegeneration. Exploring how various compounds interact with β-amyloid peptides can offer valuable insights into potential therapeutic strategies.

Objective

The objective of this research is to explore the interaction mechanisms of catechol, dopamine, and L-DOPA with β-amyloid peptides and assess their impact on peptide stability and aggregation.

Method

This study employs molecular dynamics simulations combined with density functional theory to investigate the interactions between β-amyloid and the three compounds. It evaluates changes in peptide stability and salt bridge lengths and performs electronic structure analyses using the Electron Localization Function (ELF) and Harmonic Oscillator Model of Aromaticity (HOMA).

Results

The findings reveal that β-amyloid stability decreases significantly when interacting with dopamine and L-DOPA compared to catechol. All three compounds inhibit β-amyloid, with dopamine and L-DOPA showing stronger effects. Catechol primarily interacts through hydrophobic interactions, while dopamine and L-DOPA also form hydrogen bonds with β-amyloid. Electronic structure analysis shows catechol has higher electron localization and anti-aromatic character, affecting its interactions differently than dopamine and L-DOPA. A decrease in the HOMO-LUMO gap from catechol to L-DOPA to dopamine indicates increasing reactivity towards β-amyloid.

Conclusion

Dopamine and L-DOPA more effectively disrupt β-amyloid aggregation than catechol, likely due to additional hydrogen bonding and increased electronic reactivity. These insights are crucial for developing therapeutic strategies targeting β-amyloid aggregation in Alzheimer's disease, emphasizing the importance of molecular interactions in modulating peptide stability and toxicity.

The study also provides a comparative analysis of the electronic properties and interaction dynamics of the compounds, which can guide future research in the design of β-amyloid inhibitors. The utilization of advanced simulation techniques underscores the potential for computational methods in understanding complex biological interactions and developing novel therapeutic agents. Furthermore, the insights into the differential effects of hydrophobic interactions versus hydrogen bonding offer valuable information for the synthesis of new compounds aimed at mitigating β-amyloid toxicity.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073331831241015103725
2025-01-02
2025-03-01

  • From This Site

    /content/journals/cchts/10.2174/0113862073331831241015103725
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sun X. Chen W.D. Wang Y.D. β-Amyloid: The key peptide in the pathogenesis of Alzheimer’s disease. Front. Pharmacol. 2015 6 221 10.3389/fphar.2015.00221 26483691
    [Google Scholar]
  2. Sehar U. Rawat P. Reddy A.P. Kopel J. Reddy P.H. Amyloid beta in aging and Alzheimer’s disease. Int. J. Mol. Sci. 2022 23 21 12924 10.3390/ijms232112924 36361714
    [Google Scholar]
  3. Almeaqli M.T. Alaidaa Y. Alnajjar F.M. Al Shararh A.S. Alharbi D.S. Almslmani Y.I. Alotibi Y.A. Alrashidi H.S. Shehri W.A. Hassan H.M. Al-Gayyar M.M.H. Therapeutic effects of arctiin on alzheimer’s disease-like model in rats by reducing oxidative stress, inflammasomes and fibrosis. Curr. Alzheimer Res. 2024 21 10.2174/0115672050333388240801043509 39136502
    [Google Scholar]
  4. Maziero M.P. Rocha N.P. Teixeira A.L. Antipsychotics in Alzheimer’s disease: Current status and therapeutic alternatives. Curr. Alzheimer Res. 2023 20 10 682 691 10.2174/0115672050287534240215052417 38409713
    [Google Scholar]
  5. Rodrigues J.F.R. Rodrigues L.P. de Araújo Filho G.M. Alzheimer’s disease and suicide: An integrative literature review. Curr. Alzheimer Res. 2023 20 11 758 768 10.2174/0115672050292472240216052614 38409712
    [Google Scholar]
  6. Xu J. Gou S. Huang X. Zhang J. Zhou X. Gong X. Xiong J. Chi H. Yang G. Uncovering the impact of aggrephagy in the development of alzheimer’s disease: Insights into diagnostic and therapeutic approaches from machine learning analysis. Curr. Alzheimer Res. 2023 20 9 618 635 10.2174/0115672050280894231214063023 38141185
    [Google Scholar]
  7. Abbas M. Potential role of nanoparticles in treating the accumulation of amyloid-beta peptide in Alzheimer’s patients. Polymers 2021 13 7 1051 10.3390/polym13071051 33801619
    [Google Scholar]
  8. Hernández-Zimbrón L.F. Beta amyloid peptides: Extracellular and intracellular mechanisms of clearance in Alzheimer’s disease. Update on Dementia InTech 2016
    [Google Scholar]
  9. Garden G.A. La Spada A.R. Intercellular (mis)communication in neurodegenerative disease. Neuron 2012 73 5 886 901 10.1016/j.neuron.2012.02.017 22405200
    [Google Scholar]
  10. Drolle E. Hane F. Lee B. Leonenko Z. Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer’s disease. Drug Metab. Rev. 2014 46 2 207 223 10.3109/03602532.2014.882354 24495298
    [Google Scholar]
  11. Almeida Z.L. Brito R.M.M. Structure and aggregation mechanisms in amyloids. Molecules 2020 25 5 1195 10.3390/molecules25051195 32155822
    [Google Scholar]
  12. McLaurin J. Yang D.S. Yip C.M. Fraser P.E. Review: modulating factors in amyloid-β fibril formation. J. Struct. Biol. 2000 130 2-3 259 270 10.1006/jsbi.2000.4289 10940230
    [Google Scholar]
  13. Huong V.T. Shimanouchi T. Shimauchi N. Yagi H. Umakoshi H. Goto Y. Kuboi R. Catechol derivatives inhibit the fibril formation of amyloid-β peptides. J. Biosci. Bioeng. 2010 109 6 629 634 10.1016/j.jbiosc.2009.11.010 20471605
    [Google Scholar]
  14. Li J. Zhu M. Manning-Bog A.B. Di Monte D.A. Fink A.L. Dopamine and L‐dopa disaggregate amyloid fibrils: Implications for Parkinson’s and Alzheimer’s disease. FASEB J. 2004 18 9 962 964 10.1096/fj.03‑0770fje 15059976
    [Google Scholar]
  15. Vu H.T. Shimanouchi T. Ishikawa D. Matsumoto T. Yagi H. Goto Y. Umakoshi H. Kuboi R. Effect of liposome membranes on disaggregation of amyloid β fibrils by dopamine. Biochem. Eng. J. 2013 71 118 126 10.1016/j.bej.2012.12.012
    [Google Scholar]
  16. Ramesh M. Makam P. Voshavar C. Khare H. Rajasekhar K. Ramakumar S. Govindaraju T. l -Dopa and dopamine conjugated naphthalenediimides modulate amyloid β toxicity. Org. Biomol. Chem. 2018 16 41 7682 7692 10.1039/C8OB01691G 30285025
    [Google Scholar]
  17. Tang K.J. Zhao Y. Tao X. Li J. Chen Y. Holland D.C. Jin T.Y. Wang A.Y. Xiang L. Catecholamine derivatives: Natural occurrence, structural diversity, and biological activity. J. Nat. Prod. 2023 86 11 2592 2619 10.1021/acs.jnatprod.3c00465 37856864
    [Google Scholar]
  18. Stefani M. Rigacci S. Protein folding and aggregation into amyloid: The interference by natural phenolic compounds. Int. J. Mol. Sci. 2013 14 6 12411 12457 10.3390/ijms140612411 23765219
    [Google Scholar]
  19. Le N.T.K. Kang E.J. Park J.H. Kang K. Catechol‐amyloid interactions. ChemBioChem 2023 24 24 e202300628 10.1002/cbic.202300628 37850717
    [Google Scholar]
  20. Irvine G.B. El-Agnaf O.M. Shankar G.M. Walsh D.M. Protein aggregation in the brain: The molecular basis for Alzheimer’s and Parkinson’s diseases. Mol. Med. 2008 14 7-8 451 464 10.2119/2007‑00100.Irvine 18368143
    [Google Scholar]
  21. Gnegy M.E. Catecholamines Basic Neurochemistry Academic Press 8 2012 283 299
    [Google Scholar]
  22. Gordonsmith R.H. Raxworthy M.J. Gulliver P.A. Substrate stereospecificity and selectivity of catechol-O-methyltransferase for DOPA, DOPA derivatives and α-substituted catecholamines. Biochem. Pharmacol. 1982 31 3 433 437 10.1016/0006‑2952(82)90194‑0 6803810
    [Google Scholar]
  23. Klein M.O. Battagello D.S. Cardoso A.R. Hauser D.N. Bittencourt J.C. Correa R.G. Dopamine: functions, signaling, and association with neurological diseases. Cell. Mol. Neurobiol. 2019 39 1 31 59 10.1007/s10571‑018‑0632‑3 30446950
    [Google Scholar]
  24. Juárez Olguín H. The role of dopamine and its dysfunction as a consequence of oxidative stress. Oxid Med Cell Longev 2016 2016 9730467 10.1155/2016/9730467
    [Google Scholar]
  25. Alcaro A. Huber R. Panksepp J. Behavioral functions of the mesolimbic dopaminergic system: An affective neuroethological perspective. Brain Res. Brain Res. Rev. 2007 56 2 283 321 10.1016/j.brainresrev.2007.07.014 17905440
    [Google Scholar]
  26. Nieoullon A. Coquerel A. Dopamine. Curr. Opin. Neurol. 2003 16 Suppl. 2 S3 S9 10.1097/00019052‑200312002‑00002 15129844
    [Google Scholar]
  27. Speranza L. di Porzio U. Viggiano D. de Donato A. Volpicelli F. Dopamine: The neuromodulator of long-term synaptic plasticity, reward and movement control. Cells 2021 10 4 735 10.3390/cells10040735 33810328
    [Google Scholar]
  28. Uddin M.S. Mamun A.A. Kabir M.T. Nasrullah M. Wahid F. Begum M.M. Labu Z.K. Rahman M.S. Islam M.T. Amran M.S. Abdel-Daim M.M. Neurochemistry of neurochemicals: Messengers of brain functions. Journal of Intellectual Disability - Diagnosis and Treatment 2018 5 4 137 151 10.6000/2292‑2598.2017.05.04.6
    [Google Scholar]
  29. Love T.M. Oxytocin, motivation and the role of dopamine. Pharmacol. Biochem. Behav. 2014 119 49 60 10.1016/j.pbb.2013.06.011 23850525
    [Google Scholar]
  30. Gardner E. Endocannabinoid signaling system and brain reward: Emphasis on dopamine. Pharmacol. Biochem. Behav. 2005 81 2 263 284 10.1016/j.pbb.2005.01.032 15936806
    [Google Scholar]
  31. Chakravarthy S. Balasubramani P.P. Mandali A. Jahanshahi M. Moustafa A.A. The many facets of dopamine: Toward an integrative theory of the role of dopamine in managing the body’s energy resources. Physiol. Behav. 2018 195 128 141 10.1016/j.physbeh.2018.06.032 30031088
    [Google Scholar]
  32. Sayin H. Getting high on dopamine: Neuro scientific aspects of pleasure. SexuS J 2019 4 883 906
    [Google Scholar]
  33. Rizzi G. Tan K.R. Dopamine and acetylcholine, a circuit point of view in Parkinson’s disease. Front. Neural Circuits 2017 11 110 10.3389/fncir.2017.00110 29311846
    [Google Scholar]
  34. Latif S. Jahangeer M. Maknoon Razia D. Ashiq M. Ghaffar A. Akram M. El Allam A. Bouyahya A. Garipova L. Ali Shariati M. Thiruvengadam M. Azam Ansari M. Dopamine in Parkinson’s disease. Clin. Chim. Acta 2021 522 114 126 10.1016/j.cca.2021.08.009 34389279
    [Google Scholar]
  35. Goschke T. Bolte A. Emotional modulation of control dilemmas: The role of positive affect, reward, and dopamine in cognitive stability and flexibility. Neuropsychologia 2014 62 403 423 10.1016/j.neuropsychologia.2014.07.015 25068705
    [Google Scholar]
  36. Berk M. Dodd S. Kauer-Sant’Anna M. Malhi G.S. Bourin M. Kapczinski F. Norman T. Dopamine dysregulation syndrome: Implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. 2007 116 s434 41 49 10.1111/j.1600‑0447.2007.01058.x 17688462
    [Google Scholar]
  37. Sibley D.R. Monsma F.J. Jr Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 1992 13 2 61 69 10.1016/0165‑6147(92)90025‑2 1561715
    [Google Scholar]
  38. Hauser R.A. Levodopa: past, present, and future. Eur. Neurol. 2009 62 1 1 8 10.1159/000215875 19407449
    [Google Scholar]
  39. Frii M.L. Paulson O.B. Hertz M.M. Bolwig T.G. Blood‐brain barrier permeability of L‐dopa in man. Eur. J. Clin. Invest. 1981 11 3 231 234 10.1111/j.1365‑2362.1981.tb01845.x 6791943
    [Google Scholar]
  40. Bertoldi M. Mammalian dopa decarboxylase: Structure, catalytic activity and inhibition. Arch. Biochem. Biophys. 2014 546 1 7 10.1016/j.abb.2013.12.020 24407024
    [Google Scholar]
  41. Nagatsu T. Sawada M. L-dopa therapy for Parkinson’s disease: Past, present, and future. Parkinsonism Relat. Disord. 2009 15 Suppl. 1 S3 S8 10.1016/S1353‑8020(09)70004‑5 19131039
    [Google Scholar]
  42. Bautista M.R. Identification and design of small molecules that associate with aggregated Alzheimer’s-related beta-amyloid peptides. San Diego University of California 2009
    [Google Scholar]
  43. Chen Y. Li X. Zhan C. Lao Z. Li F. Dong X. Wei G. A comprehensive insight into the mechanisms of dopamine in disrupting Aβ protofibrils and inhibiting Aβ aggregation. ACS Chem. Neurosci. 2021 12 21 4007 4019 10.1021/acschemneuro.1c00306 34472835
    [Google Scholar]
  44. Gremer L. Schölzel D. Schenk C. Reinartz E. Labahn J. Ravelli R.B.G. Tusche M. Lopez-Iglesias C. Hoyer W. Heise H. Willbold D. Schröder G.F. Fibril structure of amyloid-β(1–42) by cryo–electron microscopy. Science 2017 358 6359 116 119 10.1126/science.aao2825 28882996
    [Google Scholar]
  45. Mark P. Nilsson L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J. Phys. Chem. A 2001 105 43 9954 9960 10.1021/jp003020w
    [Google Scholar]
  46. Zhu X. Lopes P.E.M. MacKerell A.D. Jr Recent developments and applications of the CHARMM force fields. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2012 2 1 167 185 10.1002/wcms.74 23066428
    [Google Scholar]
  47. Zoete V. Cuendet M.A. Grosdidier A. Michielin O. SwissParam: A fast force field generation tool for small organic molecules. J. Comput. Chem. 2011 32 11 2359 2368 10.1002/jcc.21816 21541964
    [Google Scholar]
  48. Becke A.D. Density-functional thermochemistry. I. The effect of the exchange-only gradient correction. J. Chem. Phys. 1992 96 3 2155 2160 10.1063/1.462066
    [Google Scholar]
  49. Frisch M. Clemente F. 2009
  50. Lemak A.S. Balabaev N.K. On the Berendsen thermostat. Mol. Simul. 1994 13 3 177 187 10.1080/08927029408021981
    [Google Scholar]
  51. Hess B. Bekker H. Berendsen H.J.C. Fraaije J.G.E.M. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem. 1997 18 12 1463 1472 10.1002/(SICI)1096‑987X(199709)18:12<1463::AID‑JCC4>3.0.CO;2‑H
    [Google Scholar]
  52. Miyamoto S. Kollman P.A. Settle: An analytical version of the Shake and Rattle algorithm for rigid water models. J. Comput. Chem. 1992 13 8 952 962 10.1002/jcc.540130805
    [Google Scholar]
  53. Laskowski R.A. Swindells M.B. LigPlot+: Multiple ligand–protein interaction diagrams for drug discovery. J Chem Inf Model 2011 51 10 2778 2786
    [Google Scholar]
  54. Dubey K. Anand B.G. Badhwar R. Bagler G. Navya P.N. Daima H.K. Kar K. Tyrosine- and tryptophan-coated gold nanoparticles inhibit amyloid aggregation of insulin. Amino Acids 2015 47 12 2551 2560 10.1007/s00726‑015‑2046‑6 26193769
    [Google Scholar]
  55. Amaro M. Birch D.J.S. Rolinski O.J. Beta-amyloid oligomerisation monitored by intrinsic tyrosine fluorescence. Phys. Chem. Chem. Phys. 2011 13 14 6434 6441 10.1039/c0cp02652b 21373703
    [Google Scholar]
  56. Becke A.D. Edgecombe K.E. A simple measure of electron localization in atomic and molecular systems. J. Chem. Phys. 1990 92 9 5397 5403 10.1063/1.458517
    [Google Scholar]
  57. Tian L.U. Fei-Wu C.H.E.N. LU T. and F.-W. CHEN, Meaning and functional form of the electron localization function. Wuli Huaxue Xuebao 2011 27 12 2786 2792 10.3866/PKU.WHXB20112786
    [Google Scholar]
  58. Zhang L. Zhang Y. Zhang Y. Gamal El-Din M. Application of an indigenous microorganisms-based fixed-bed GAC-biofilm reactor for passive and sustainable treatment of oil sands process water through combined adsorption and biodegradation processes. Chemosphere 2021 280 130635 10.1016/j.chemosphere.2021.130635 33964752
    [Google Scholar]
  59. Wang W. Zhang C. Jin Y. Li S. Zhang W. Kong P. Xie C. Du C. Liu Q. Zhang C. Structural, mechanical and electronic properties and hardness of ionic vanadium dihydrides under pressure from first-principles computations. Sci. Rep. 2020 10 1 8868 10.1038/s41598‑020‑65910‑4 32483252
    [Google Scholar]
  60. Bozorgmehr M.R. Chamani J. Moslehi G. Spectroscopic and DFT investigation of interactions between cyclophosphamide and aspirin with lysozyme as binary and ternary systems. J. Biomol. Struct. Dyn. 2015 33 8 1669 1681 10.1080/07391102.2014.967299 25301295
    [Google Scholar]
  61. Lu T. dd 2014
    [Google Scholar]
  62. Kruszewski J. Krygowski T.M. Definition of aromaticity basing on the harmonic oscillator model. Tetrahedron Lett. 1972 13 36 3839 3842 10.1016/S0040‑4039(01)94175‑9
    [Google Scholar]
  63. Dobrowolski J.C. Ostrowski S. HOMA index establishes similarity to a reference molecule. J. Chem. Inf. Model. 2023 63 24 7744 7754 10.1021/acs.jcim.3c01551 38055931
    [Google Scholar]
  64. Gong C. Wang W. Bowen K. Zhang X. Stable parent anions of dopamine and adrenaline: A new form of neurotransmitters. J. Phys. Chem. B 2019 123 36 7695 7699 10.1021/acs.jpcb.9b06223 31429554
    [Google Scholar]
  65. Huang Y. Rong C. Zhang R. Liu S. Evaluating frontier orbital energy and HOMO/LUMO gap with descriptors from density functional reactivity theory. J. Mol. Model. 2017 23 1 3 10.1007/s00894‑016‑3175‑x 27933419
    [Google Scholar]
  66. Miar M. Shiroudi A. Pourshamsian K. Oliaey A.R. Hatamjafari F. Theoretical investigations on the HOMO–LUMO gap and global reactivity descriptor studies, natural bond orbital, and nucleus-independent chemical shifts analyses of 3-phenylbenzo[ d ]thiazole-2(3 H )-imine and its para -substituted derivatives: Solvent and substituent effects. J. Chem. Res. 2021 45 1-2 147 158 10.1177/1747519820932091
    [Google Scholar]
  67. Aihara J. Correlation found between the HOMO–LUMO energy separation and the chemical reactivity at the most reactive site for isolated-pentagon isomers of fullerenes. Phys. Chem. Chem. Phys. 2000 2 14 3121 3125 10.1039/b002601h
    [Google Scholar]
  68. Chandel T.I. Zaman M. Khan M.V. Ali M. Rabbani G. Ishtikhar M. Khan R.H. A mechanistic insight into protein-ligand interaction, folding, misfolding, aggregation and inhibition of protein aggregates: An overview. Int. J. Biol. Macromol. 2018 106 1115 1129 10.1016/j.ijbiomac.2017.07.185 28890370
    [Google Scholar]
  69. Ziehm T. Buell A.K. Willbold D. Role of hydrophobicity and charge of amyloid-beta oligomer eliminating d-peptides in the interaction with amyloid-beta monomers. ACS Chem. Neurosci. 2018 9 11 2679 2688 10.1021/acschemneuro.8b00132 29893543
    [Google Scholar]
  70. Jabbar M.L. Computational studies on electronic and optical properties of dopamine derivatives structure: A DFT study **. J. Mech. Behav. Mater. 2021 30 1 279 284 10.1515/jmbm‑2021‑0030
    [Google Scholar]
/content/journals/cchts/10.2174/0113862073331831241015103725
Loading
Unveiling the Interplay between Dopamine-like Molecules and Β-Amyloid Peptide: A Combined Molecular Dynamic and DFT Approach
Bentham Science Publishers ; https://doi.org/10.2174/0113862073331831241015103725
/content/journals/cchts/10.2174/0113862073331831241015103725
/content/journals/cchts/10.2174/0113862073331831241015103725
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: protein-ligand interaction ; dopamine ; β-amyloid peptide ; alzheimer's disease ; catechol ; frontier orbital

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test